UCB amends and extends revolver
Belgian biopharmaceutical company UCB has extended the maturity of its revolving credit from 2012 to 2015, reducing the size of the loan from Eu1.5bn to Eu1bn.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
